EE200300015A - Kolhinooli derivaadid kui angiogeneesi inhibiitorid - Google Patents

Kolhinooli derivaadid kui angiogeneesi inhibiitorid

Info

Publication number
EE200300015A
EE200300015A EEP200300015A EEP200300015A EE200300015A EE 200300015 A EE200300015 A EE 200300015A EE P200300015 A EEP200300015 A EE P200300015A EE P200300015 A EEP200300015 A EE P200300015A EE 200300015 A EE200300015 A EE 200300015A
Authority
EE
Estonia
Prior art keywords
angiogenesis
inhibitors
colchinol derivatives
colchinol
derivatives
Prior art date
Application number
EEP200300015A
Other languages
English (en)
Estonian (et)
Inventor
Claude Arnould Jean
Original Assignee
Angiogene Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiogene Pharmaceuticals Limited filed Critical Angiogene Pharmaceuticals Limited
Publication of EE200300015A publication Critical patent/EE200300015A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/30—Ortho- or ortho- and peri-condensed systems containing three rings containing seven-membered rings
    • C07C2603/32—Dibenzocycloheptenes; Hydrogenated dibenzocycloheptenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200300015A 2000-07-07 2001-07-04 Kolhinooli derivaadid kui angiogeneesi inhibiitorid EE200300015A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00401977 2000-07-07
EP00401976 2000-07-07
PCT/GB2001/002964 WO2002008213A1 (en) 2000-07-07 2001-07-04 Colchinol derivatives as angiogenesis inhibitors

Publications (1)

Publication Number Publication Date
EE200300015A true EE200300015A (et) 2004-10-15

Family

ID=26073520

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300015A EE200300015A (et) 2000-07-07 2001-07-04 Kolhinooli derivaadid kui angiogeneesi inhibiitorid

Country Status (19)

Country Link
EP (1) EP1301498A1 (cs)
JP (1) JP2004504391A (cs)
KR (1) KR20030022264A (cs)
CN (1) CN1255392C (cs)
AU (2) AU6623201A (cs)
BR (1) BR0112225A (cs)
CA (1) CA2410562A1 (cs)
CZ (1) CZ200331A3 (cs)
EE (1) EE200300015A (cs)
HU (1) HUP0301742A3 (cs)
IL (1) IL153325A0 (cs)
IS (1) IS6668A (cs)
MX (1) MXPA02012903A (cs)
NO (1) NO20030055L (cs)
NZ (1) NZ522661A (cs)
PL (1) PL359181A1 (cs)
RU (1) RU2003103603A (cs)
SK (1) SK52003A3 (cs)
WO (1) WO2002008213A1 (cs)

Families Citing this family (330)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
US6720323B2 (en) 2000-07-07 2004-04-13 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
AU2003202094B2 (en) 2002-02-01 2009-10-08 Astrazeneca Ab Quinazoline compounds
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
ATE381546T1 (de) 2002-08-24 2008-01-15 Astrazeneca Ab Pyrimidinderivate als modulatoren der aktivitut von chemokinrezeptoren
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
ATE370958T1 (de) 2002-12-24 2007-09-15 Astrazeneca Ab Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung
CA2516078C (en) 2003-02-28 2014-04-29 Oxigene, Inc. Catechol compositions and use thereof
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
US7485643B2 (en) 2003-11-19 2009-02-03 Array Biopharma Inc. Bicyclic inhibitors of MEK and methods of use thereof
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
RU2397168C2 (ru) 2004-01-05 2010-08-20 Астразенека Аб Производные тиофена в качестве ингибиторов снк 1
SE0401657D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
NZ553335A (en) 2004-08-28 2010-05-28 Astrazeneca Ab Pyrimidine sulphonamide (sulfonamide) derivatives as chemokine receptor modulators
BRPI0519596B1 (pt) 2004-12-21 2022-01-18 Astrazeneca Ab Agente de ligação alvejado, anticorpo monoclonal que se liga a angiopoietina-2, molécula de ácido nucleico, vetor, e, uso do agente de ligação alvejado
BRPI0606793A8 (pt) 2005-02-04 2018-03-13 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação e uso do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de câncer e para a produção de um efeito anti-proliferativo em um animal de sangue quente, e, composição farmacêutica
EP1922307B1 (en) 2005-05-18 2011-12-28 Array Biopharma, Inc. Heterocyclic inhibitors of mek and methods of use thereof
RU2008105987A (ru) 2005-07-21 2009-08-27 Астразенека Аб (Se) Новые пиперидиновые производные
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
US20090118263A1 (en) 2005-09-22 2009-05-07 Dainippon Sumitomo Pharma Co., Ltd. Novel Adenine Compound
WO2007034916A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
WO2007034881A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
WO2007034917A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規なアデニン化合物
WO2007034882A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
JP5155171B2 (ja) 2005-10-06 2013-02-27 アストラゼネカ・アクチエボラーグ 新規化合物
WO2007049041A1 (en) 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
SI1971601T1 (sl) 2005-11-15 2010-03-31 Array Biopharma Inc N fenil kinazolin aminski derivati in sorodne spojine kot inhibitorji ERBB tip I receptorske tirozin kinaze za zdravljenje hiperproliferativnih bolezni
TW200730512A (en) 2005-12-12 2007-08-16 Astrazeneca Ab Novel compounds
HRP20120421T1 (hr) 2005-12-13 2012-07-31 Medimmune@Limited Vezni proteini specifični za inzulinu slične čimbenike rasta i njihova upotreba
TW200732296A (en) 2005-12-15 2007-09-01 Astrazeneca Ab Novel compounds
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
JP2009538289A (ja) 2006-05-26 2009-11-05 アストラゼネカ・アクチエボラーグ ビアリールまたはヘテロアリール置換インドール
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
DE102006037478A1 (de) 2006-08-10 2008-02-14 Merck Patent Gmbh 2-(Heterocyclylbenzyl)-pyridazinonderivate
PL2057156T3 (pl) 2006-08-23 2017-08-31 Kudos Pharmaceuticals Limited Pochodne 2-metylomorfolinowe pirydo-, pirazo- i pirymido-pirymidyny jako inhibitory mTOR
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
US20100113510A1 (en) 2006-12-19 2010-05-06 Rhonan Ford Quinuclidinol derivatives as muscarinic receptor antagonists
CL2008000191A1 (es) 2007-01-25 2008-08-22 Astrazeneca Ab Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
TW200902018A (en) 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Novel adenine compound
JPWO2008114819A1 (ja) 2007-03-20 2010-07-08 大日本住友製薬株式会社 新規アデニン化合物
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
DE102007025718A1 (de) 2007-06-01 2008-12-04 Merck Patent Gmbh Pyridazinonderivate
DE102007025717A1 (de) 2007-06-01 2008-12-11 Merck Patent Gmbh Arylether-pyridazinonderivate
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007038957A1 (de) 2007-08-17 2009-02-19 Merck Patent Gmbh 6-Thioxo-pyridazinderivate
DE102007041115A1 (de) 2007-08-30 2009-03-05 Merck Patent Gmbh Thiadiazinonderivate
BRPI0817941A2 (pt) 2007-10-04 2015-05-05 Astrazeneca Ab Compostos de pirazol de [3,2-c] esteroidais, com atividade glucocorticóide
CN101861321B (zh) 2007-10-11 2013-02-06 阿斯利康(瑞典)有限公司 作为蛋白激酶b抑制剂的吡咯并[2,3-d]嘧啶衍生物
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
KR101620539B1 (ko) 2007-12-21 2016-05-13 메디뮨 리미티드 인터루킨-4 수용체 알파(ＩＬ-4Ｒα)에 대한 결합 구성원-173
ME01532B (me) 2008-02-06 2014-04-20 Astrazeneca Ab Jedinjenja
CN101952287B (zh) 2008-02-28 2013-11-27 默克专利有限公司 蛋白激酶抑制剂及其应用
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
PL2297106T3 (pl) 2008-05-27 2015-01-30 Galderma Sa Pochodne fenoksypirydynyloamidu i ich zastosowania w leczeniu chorób, w których pośredniczy pde4
DE102008025750A1 (de) 2008-05-29 2009-12-03 Merck Patent Gmbh Dihydropyrazolderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
DE102008029734A1 (de) 2008-06-23 2009-12-24 Merck Patent Gmbh Thiazolyl-piperidinderivate
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
CA2735900A1 (en) 2008-09-19 2010-03-25 Medimmune, Llc Antibodies directed to dll4 and uses thereof
DE102008052943A1 (de) 2008-10-23 2010-04-29 Merck Patent Gmbh Azaindolderivate
WO2010067102A1 (en) 2008-12-09 2010-06-17 Astrazeneca Ab Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
AU2009324489B2 (en) 2008-12-11 2015-11-12 Axcentua Pharmaceuticals Ab Crystalline forms of genistein
US7863325B2 (en) 2008-12-11 2011-01-04 Axcentua Pharmaceuticals Ab Crystalline genistein sodium salt dihydrate
US20100152197A1 (en) 2008-12-15 2010-06-17 Astrazeneca Ab (4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
ES2550101T3 (es) 2008-12-17 2015-11-04 Merck Patent Gmbh Inhibidores de proteína quinasa de benzonaftiridinona tricíclica modificada con anillo C y su uso
DE102008063667A1 (de) 2008-12-18 2010-07-01 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
CA2745085C (en) 2008-12-18 2018-03-06 Merck Patent Gmbh Tricyclic azaindoles
US20110053923A1 (en) 2008-12-22 2011-03-03 Astrazeneca Chemical compounds 610
DE102008062825A1 (de) 2008-12-23 2010-06-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
JP2012513194A (ja) 2008-12-23 2012-06-14 アストラゼネカ アクチボラグ α５β１に向けられた標的結合剤およびその使用
DE102008062826A1 (de) 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
DE102009003975A1 (de) 2009-01-07 2010-07-08 Merck Patent Gmbh Benzothiazolonderivate
DE102009003954A1 (de) 2009-01-07 2010-07-08 Merck Patent Gmbh Pyridazinonderivate
DE102009004061A1 (de) 2009-01-08 2010-07-15 Merck Patent Gmbh Pyridazinonderivate
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
CA2749926A1 (en) 2009-02-10 2010-08-19 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
GB0905127D0 (en) 2009-03-25 2009-05-06 Pharminox Ltd Novel prodrugs
UY32520A (es) 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
US20100317593A1 (en) 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
DE102009043260A1 (de) 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolonderivate
MX2012003644A (es) 2009-10-02 2012-04-30 Astrazeneca Ab Compuestos de 2-piridona empleados como inhibidores de la elastasa neutrofila.
DE102009049679A1 (de) 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
WO2011048409A1 (en) 2009-10-20 2011-04-28 Astrazeneca Ab Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
TW201121957A (en) 2009-11-18 2011-07-01 Astrazeneca Ab Benzoimidazole compounds and uses thereof
SI2504364T1 (sl) 2009-11-24 2017-11-30 Medimmune Limited Usmerjena vezavna sredstva proti B7-H1
JP2013512859A (ja) 2009-12-03 2013-04-18 大日本住友製薬株式会社 トール様受容体（ｔｌｒ）を介して作用するイミダゾキノリン
DE102009058280A1 (de) 2009-12-14 2011-06-16 Merck Patent Gmbh Thiazolderivate
AU2010333338A1 (en) 2009-12-14 2012-08-02 Merck Patent Gmbh Sphingosine kinase inhibitors
US8907098B2 (en) 2009-12-17 2014-12-09 Merck Patent Gmbh Inhibitors of sphingosine kinase
WO2011085641A1 (en) 2010-01-15 2011-07-21 Suzhou Neupharma Co., Ltd. Certain chemical entities, compositions, and methods
RU2012135093A (ru) 2010-01-19 2014-03-10 Астразенека Аб Производные пиразина
WO2011095807A1 (en) 2010-02-07 2011-08-11 Astrazeneca Ab Combinations of mek and hh inhibitors
WO2011114148A1 (en) 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
US20130059916A1 (en) 2010-05-26 2013-03-07 Stephane Rocchi Biguanide compounds and its use for treating cancer
WO2011154677A1 (en) 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
TW201219383A (en) 2010-08-02 2012-05-16 Astrazeneca Ab Chemical compounds
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
DE102010034699A1 (de) 2010-08-18 2012-02-23 Merck Patent Gmbh Pyrimidinderivate
US9018197B2 (en) 2010-08-28 2015-04-28 Suzhou Neupharma Co. Ltd. Tetradecahydro-1H-cyclopenta[a]phenanthrene compounds, compositions, and related methods of use
GB201016442D0 (en) 2010-09-30 2010-11-17 Pharminox Ltd Novel acridine derivatives
DE102010048800A1 (de) 2010-10-20 2012-05-10 Merck Patent Gmbh Chinoxalinderivate
DE102010049595A1 (de) 2010-10-26 2012-04-26 Merck Patent Gmbh Chinazolinderivate
WO2012066335A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Phenol compounds als toll -like receptor 7 agonists
WO2012067269A1 (en) 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease
WO2012066336A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Benzylamine compounds as toll -like receptor 7 agonists
JP2013542916A (ja) 2010-11-19 2013-11-28 大日本住友製薬株式会社 環状アミド化合物および疾患の処置におけるその使用
CN103370317B (zh) 2010-12-16 2015-10-07 阿斯利康(瑞典)有限公司 可用于治疗的咪唑并[4,5-c]喹啉-1-基衍生物
JP5978226B2 (ja) 2010-12-17 2016-08-24 大日本住友製薬株式会社 プリン誘導体
US9255144B2 (en) 2010-12-20 2016-02-09 Medimmune Limited Anti-IL-18 antibodies and their uses
EP2670763B1 (en) 2011-02-02 2018-08-01 Suzhou Neupharma Co., Ltd Certain chemical entities, compositions, and methods
ES2724525T3 (es) 2011-02-17 2019-09-11 Cancer Therapeutics Crc Pty Ltd Inhibidores selectivos de FAK
DK2675793T3 (en) 2011-02-17 2018-11-12 Cancer Therapeutics Crc Pty Ltd FAK INHIBITORS
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
US8530470B2 (en) 2011-04-13 2013-09-10 Astrazeneca Ab Chromenone derivatives
WO2012175991A1 (en) 2011-06-24 2012-12-27 Pharminox Limited Fused pentacyclic anti - proliferative compounds
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
SMT202100173T1 (it) 2011-07-12 2021-05-07 Astrazeneca Ab N-(6-((2r,3s)-3,4-diidrossibutan-2-ilossi)-2-(4-fluorobenziltio)pirimidin-4-il)-3-metilazetidin-1-solfonammide come modulatore di recettori di chemochine
EP3333161B1 (en) 2011-07-27 2020-02-19 Astrazeneca AB 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer
DE102011111400A1 (de) 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
CN104053442B (zh) 2011-08-26 2017-06-23 润新生物公司 某些化学实体、组合物及方法
EP2753174A4 (en) 2011-09-01 2015-05-20 Xiangping Qian PARTICULAR CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
CN108794411B (zh) 2011-09-14 2022-06-07 润新生物公司 某些化学实体、组合物及方法
WO2013043935A1 (en) 2011-09-21 2013-03-28 Neupharma, Inc. Certain chemical entites, compositions, and methods
EP2760458B1 (en) 2011-09-29 2017-06-14 The University of Liverpool Prevention and/or treatment of cancer and/or cancer metastasis
US9249111B2 (en) 2011-09-30 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-RAF kinase inhibitors
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
US9670180B2 (en) 2012-01-25 2017-06-06 Neupharma, Inc. Certain chemical entities, compositions, and methods
EP2807161B1 (en) 2012-01-28 2017-10-04 Merck Patent GmbH Triazolo[4,5-d]pyrimidine derivatives
WO2013117288A1 (en) 2012-02-09 2013-08-15 Merck Patent Gmbh Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
DK2812337T3 (en) 2012-02-09 2016-11-07 Merck Patent Gmbh Furo [3,2-B] pyridine derivatives as TBK1 AND IKK INHIBITORS
AU2013224421B2 (en) 2012-02-21 2017-03-02 Merck Patent Gmbh 8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors
CA2865040C (en) 2012-02-21 2020-07-14 Merck Patent Gmbh Cyclic diaminopyrimidine derivatives
WO2013124025A1 (en) 2012-02-21 2013-08-29 Merck Patent Gmbh Furopyridine derivatives
WO2013131609A1 (en) 2012-03-07 2013-09-12 Merck Patent Gmbh Triazolopyrazine derivatives
PT2831077T (pt) 2012-03-28 2016-08-12 Merck Patent Gmbh Derivados bicíclicos pirazinona
WO2013144532A1 (en) 2012-03-30 2013-10-03 Astrazeneca Ab 3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
AU2013244999A1 (en) 2012-04-05 2014-09-25 F. Hoffmann-La Roche Ag Bispecific antibodies against human TWEAK and human IL17 and uses thereof
US9676813B2 (en) 2012-04-29 2017-06-13 Neupharma, Inc. Certain steroids and methods for using the same in the treatment of cancer
MX357502B (es) 2012-05-04 2018-07-12 Merck Patent Gmbh Derivados de pirrolotriazinona.
GB201211021D0 (en) 2012-06-21 2012-08-01 Cancer Rec Tech Ltd Pharmaceutically active compounds
CN104507957B (zh) 2012-07-24 2018-12-25 默克专利股份有限公司 用于治疗关节病的羟基他汀衍生物
AU2013301865B2 (en) 2012-08-07 2017-08-17 Merck Patent Gmbh Pyridopyrimidine derivatives as protein kinase inhibitors
AU2013301870B2 (en) 2012-08-08 2017-04-27 Merck Patent Gmbh (Aza-)isoquinolinone derivatives
US20160009686A1 (en) 2012-08-17 2016-01-14 Cancer Therapeutics Crc Pty Limited Vegfr3 inhibitors
WO2014041349A1 (en) 2012-09-12 2014-03-20 Cancer Therapeutics Crc Pty Ltd Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
EP2897618B1 (en) 2012-09-24 2021-11-17 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9388142B2 (en) 2012-09-26 2016-07-12 Merck Patent Gmbh Quinazolinone derivatives as PARP inhibitors
JP6348115B2 (ja) 2012-10-26 2018-06-27 ザ ユニバーシティー オブ クイーンズランド がん療法のためのエンドサイトーシス阻害剤および抗体の使用
WO2014066955A1 (en) 2012-11-05 2014-05-08 Lindley Robyn Alice Methods for determining the cause of somatic mutagenesis
WO2014075077A1 (en) 2012-11-12 2014-05-15 Neupharma, Inc. Certain chemical entities, compositions, and methods
ES2608355T3 (es) 2012-11-16 2017-04-10 Merck Patent Gmbh Derivados de 3-aminociclopentanocarboxamida.
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
CN107485612B (zh) 2013-01-31 2021-03-30 尼奥迈德研究所 咪唑并吡啶化合物及其用途
US9663475B2 (en) 2013-02-25 2017-05-30 Merck Patent Gmbh 2 amino-3,4-dihydrcquinazoline derivatives and the use thereof as cathepsin D inhibitors
AU2014224976B2 (en) 2013-03-05 2017-09-28 Merck Patent Gmbh 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
CN105142648A (zh) 2013-03-15 2015-12-09 玛格塞蒂克斯公司 用于癌症的镁组合物及其用途
AR095443A1 (es) 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii Heterociclos condensados con acción sobre atr
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
WO2014195507A1 (en) 2013-06-07 2014-12-11 Universite Catholique De Louvain 3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
JP6802063B2 (ja) 2013-06-25 2020-12-16 エピアクシス セラピューティクス プロプライエタリー リミテッド 癌幹細胞を調節するための方法および組成物
CN111285813A (zh) 2013-08-23 2020-06-16 润新生物公司 化学实体、组合物和方法
EP3046560B1 (en) 2013-09-18 2021-01-06 EpiAxis Therapeutics Pty Ltd Stem cell modulation ii
WO2015048852A1 (en) 2013-10-01 2015-04-09 The University Of Queensland Kits and methods for diagnosis, screening, treatment and disease monitoring
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
US10485772B2 (en) 2014-08-25 2019-11-26 EpiAxis Therapeutics Pty Ltd. Compositions for modulating cancer stem cells and uses therefor
EP3221701B1 (en) 2014-11-17 2021-03-31 The University of Queensland Glycoprotein biomarkers for esophageal adenocarcinoma and barrett's esophagus and uses thereof
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
WO2016133935A1 (en) 2015-02-17 2016-08-25 Neupharma, Inc. Certain chemical entities, compositions, and methods
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
USRE49850E1 (en) 2015-08-04 2024-02-27 Aucentra Therapeutics Pty Ltd N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
CN108603231B (zh) 2015-08-26 2023-06-30 Gmdx私人有限公司 检测癌症复发的方法
SG11201805341RA (en) 2015-12-23 2018-07-30 Univ Queensland Technology Nucleic acid oligomers and uses therefor
SG11201806122YA (en) 2016-02-01 2018-08-30 Univ Canberra Proteinaceous compounds and uses therefor
TWI827530B (zh) 2016-02-15 2024-01-01 瑞典商阿斯特捷利康公司 包括對西地尼布進行固定的間歇給藥之方法
EP3442535B1 (en) 2016-04-15 2022-06-01 Cancer Research Technology Limited Heterocyclic compounds as ret kinase inhibitors
GB2554333A (en) 2016-04-26 2018-04-04 Big Dna Ltd Combination therapy
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
RU2768827C2 (ru) 2016-07-29 2022-03-24 ФЛЭкс БАЙО, ИНК. Модуляторы хемокинового рецептора и их применение
AU2017312561B2 (en) 2016-08-15 2022-06-30 Neupharma, Inc. Certain chemical entities, compositions, and methods
ES2845048T3 (es) 2016-09-22 2021-07-23 Cancer Research Tech Ltd Preparación y usos de derivados de pirimidinona
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
US10786502B2 (en) 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
WO2018106606A1 (en) 2016-12-05 2018-06-14 Apros Therapeutics, Inc. Pyrimidine compounds containing acidic groups
WO2018141002A2 (en) 2017-02-01 2018-08-09 University Of South Australia DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
US10703723B2 (en) 2017-03-09 2020-07-07 Truly Translational Sweden Ab Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
GB201704325D0 (en) 2017-03-17 2017-05-03 Argonaut Therapeutics Ltd Compounds
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
CN108864079B (zh) 2017-05-15 2021-04-09 深圳福沃药业有限公司 一种三嗪化合物及其药学上可接受的盐
JP7202315B2 (ja) 2017-05-26 2023-01-11 キャンサー・リサーチ・テクノロジー・リミテッド ベンズイミダゾロン由来のｂｃｌ６阻害剤
ES2975661T3 (es) 2017-05-26 2024-07-11 Cancer Research Tech Ltd Inhibidores de BCL6 derivados de la 2-quinolona
EP3630188B1 (en) 2017-05-31 2021-08-25 Amplio Pharma AB A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy
EP3648797A1 (en) 2017-07-05 2020-05-13 EPOS-Iasis Research and Development, Ltd Multifunctional conjugates
US11186592B2 (en) 2017-08-01 2021-11-30 Merck Patent Gmbh Thiazolopyridine derivatives as adenosine receptor antagonists
EP3668882A1 (en) 2017-08-18 2020-06-24 Cancer Research Technology Limited Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer
DK3672951T3 (da) 2017-08-21 2023-11-20 Merck Patent Gmbh Quinoxalinderivater som adenosinreceptorantagonister
KR20200043433A (ko) 2017-08-21 2020-04-27 메르크 파텐트 게엠베하 아데노신 수용체 길항제로서의 벤즈이미다졸 유도체
TWI702205B (zh) 2017-10-06 2020-08-21 俄羅斯聯邦商拜奧卡德聯合股份公司 表皮生長因子受體抑制劑
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
NL2019801B1 (en) 2017-10-25 2019-05-02 Univ Leiden Delivery vectors
SG11202004105TA (en) 2017-11-06 2020-06-29 Rapt Therapeutics Inc Anticancer agents
EP3488868B1 (en) 2017-11-23 2023-09-13 medac Gesellschaft für klinische Spezialpräparate mbH Pharmaceutical composition for oral administration containing sulfasalazine and / or a sulfasalazine organic salt, production process and use
EP3489222A1 (en) 2017-11-23 2019-05-29 medac Gesellschaft für klinische Spezialpräparate mbH Sulfasalazine salts, production processes and uses
CN111757881B (zh) 2018-01-15 2024-05-07 澳升医药公司 作为治疗剂的5-(嘧啶-4-基)噻唑-2-基脲衍生物
GB201801128D0 (en) 2018-01-24 2018-03-07 Univ Oxford Innovation Ltd Compounds
JP7355758B2 (ja) 2018-01-26 2023-10-03 ラプト・セラピューティクス・インコーポレイテッド ケモカイン受容体調節剤及びその使用
WO2019157225A2 (en) 2018-02-08 2019-08-15 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2019175093A1 (en) 2018-03-12 2019-09-19 Astrazeneca Ab Method for treating lung cancer
SG11202009735QA (en) 2018-04-13 2020-10-29 Cancer Research Tech Ltd Bcl6 inhibitors
WO2019210266A1 (en) 2018-04-27 2019-10-31 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
GB201809102D0 (en) 2018-06-04 2018-07-18 Univ Oxford Innovation Ltd Compounds
TW202003475A (zh) 2018-06-04 2020-01-16 美商亞博創新醫藥有限公司 含酸性基團之嘧啶化合物
WO2019236631A1 (en) 2018-06-05 2019-12-12 Rapt Therapeutics, Inc. Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
RS66314B1 (sr) 2018-09-18 2025-01-31 Hoffmann La Roche Derivati hinazolina kao antitumorski agensi
WO2020068600A1 (en) 2018-09-24 2020-04-02 Rapt Therapeutics, Inc. Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof
EP3870582B1 (en) 2018-10-25 2023-07-19 Merck Patent GmbH 5-azaindazole derivatives as adenosine receptor antagonists
WO2020083856A1 (en) 2018-10-25 2020-04-30 Merck Patent Gmbh 5-azaindazole derivatives as adenosine receptor antagonists
GB201819126D0 (en) 2018-11-23 2019-01-09 Cancer Research Tech Ltd Inhibitor compounds
EP3960858B1 (en) 2018-12-25 2025-05-07 Beijing Baishihekang Pharmaceutical Technology (BSJpharma) Co., Ltd. Small rna medicament for prevention and treatment of inflammation-related diseases and combination thereof
AR117844A1 (es) 2019-01-22 2021-09-01 Merck Patent Gmbh Derivados de tiazolopiridina como antagonistas del receptor de adenosina
EP3935049A1 (en) 2019-03-07 2022-01-12 Merck Patent GmbH Carboxamide-pyrimidine derivatives as shp2 antagonists
KR102861189B1 (ko) 2019-03-28 2025-09-16 앰플리아 테라퓨틱스 리미티드 Fak 억제제의 염 및 결정 형태
KR20210144844A (ko) 2019-03-29 2021-11-30 아스트라제네카 아베 비-소세포 폐암의 치료에 사용하기 위한 오시머티닙
CN111747950B (zh) 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物
US12358915B2 (en) 2019-04-05 2025-07-15 STORM Therapeutics Ltd. METTL3 inhibitory compounds
WO2020210384A1 (en) 2019-04-08 2020-10-15 Merck Patent Gmbh Pyrimidinone derivatives as shp2 antagonists
GB201905328D0 (en) 2019-04-15 2019-05-29 Azeria Therapeutics Ltd Inhibitor compounds
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
GB201908885D0 (en) 2019-06-20 2019-08-07 Storm Therapeutics Ltd Therapeutic compounds
CA3152674A1 (en) 2019-08-31 2021-03-04 Etern Biopharma (Shanghai) Co., Ltd. Pyrazole derivatives for fgfr inhibitor and preparation method thereof
KR20220066922A (ko) 2019-09-20 2022-05-24 아이디어야 바이오사이언시스 인코포레이티드 Parg 억제제로서 4-치환된 인돌 및 인다졸 설폰아미도 유도체
GB201913988D0 (en) 2019-09-27 2019-11-13 Celleron Therapeutics Ltd Novel treatment
GB201914860D0 (en) 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds
GB201915829D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915831D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915828D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
KR20220113431A (ko) 2019-12-02 2022-08-12 스톰 테라퓨틱스 리미티드 Mettl3 저해제로서의 폴리헤테로환식 화합물
GB202004960D0 (en) 2020-04-03 2020-05-20 Kinsenus Ltd Inhibitor compounds
US20230183197A1 (en) 2020-06-01 2023-06-15 Neophore Limited Inhibitors of mlh1 and/or pms2 for cancer treatment
GB202012482D0 (en) 2020-08-11 2020-09-23 Univ Of Huddersfield Novel compounds and therapeutic uses thereof
GB202012969D0 (en) 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds
WO2022074379A1 (en) 2020-10-06 2022-04-14 Storm Therapeutics Limited Mettl3 inhibitory compounds
US20240101589A1 (en) 2020-10-08 2024-03-28 Strom Therapeutics Limited Inhibitors of mettl3
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
GB202102895D0 (en) 2021-03-01 2021-04-14 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2022197641A1 (en) 2021-03-15 2022-09-22 Rapt Therapeutics, Inc. 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
US20250281633A1 (en) 2021-05-03 2025-09-11 Merck Patent Gmbh Her2 targeting fc antigen binding fragment-drug conjugates
WO2022245061A1 (ko) 2021-05-17 2022-11-24 에이치케이이노엔 주식회사 벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CA3221411A1 (en) 2021-05-25 2022-12-01 Merck Patent Gmbh Egfr targeting fc antigen binding fragment-drug conjugates
GB202107907D0 (en) 2021-06-02 2021-07-14 Storm Therapeutics Ltd Combination therapies
GB202108383D0 (en) 2021-06-11 2021-07-28 Argonaut Therapeutics Ltd Compounds useful in the treatment or prevention of a prmt5-mediated disorder
GB202110373D0 (en) 2021-07-19 2021-09-01 Neophore Ltd Inhibitor compounds
CA3225500A1 (en) 2021-10-04 2023-04-13 Ulrich Luecking Parg inhibitory compounds
US20250002491A1 (en) 2021-10-04 2025-01-02 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
GB202117224D0 (en) 2021-11-29 2022-01-12 Neophore Ltd Inhibitor compounds
GB202117225D0 (en) 2021-11-29 2022-01-12 Neophore Ltd Protac compounds
IL314200A (en) 2022-01-10 2024-09-01 Merck Patent Gmbh Heterocycles are being converted as HSET inhibitors
GB202202006D0 (en) 2022-02-15 2022-03-30 Chancellor Masters And Scholars Of The Univ Of Oxford Anti-cancer treatment
GB202202199D0 (en) 2022-02-18 2022-04-06 Cancer Research Tech Ltd Compounds
WO2023175184A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
WO2023175185A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
GB202204935D0 (en) 2022-04-04 2022-05-18 Cambridge Entpr Ltd Nanoparticles
JP2025512963A (ja) 2022-04-06 2025-04-22 ラプト・セラピューティクス・インコーポレイテッド ケモカイン受容体モジュレータ及びその使用
US20250304576A1 (en) 2022-05-11 2025-10-02 Cancer Research Technology Limited Ikk inhibitors
GB202209404D0 (en) 2022-06-27 2022-08-10 Univ Of Sussex Compounds
WO2024030825A1 (en) 2022-08-01 2024-02-08 Neupharma, Inc Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
GB202213164D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213166D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213162D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Prodrugs
GB202213167D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213163D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
AU2023355735A1 (en) 2022-10-03 2025-04-03 Forx Therapeutics Ag Parg inhibitory compound
EP4612148A1 (en) 2022-11-02 2025-09-10 Cancer Research Technology Limited 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
WO2024094962A1 (en) 2022-11-02 2024-05-10 Cancer Research Technology Limited Pyrido[2,3-d]pyrimidin-2-amine derivatives as egfr inhibitors for the treatment of cancer
WO2024099898A1 (en) 2022-11-07 2024-05-16 Merck Patent Gmbh Substituted bi-and tricyclic hset inhibitors
GB202218672D0 (en) 2022-12-12 2023-01-25 Storm Therapeutics Ltd Inhibitory compounds
GB202300881D0 (en) 2023-01-20 2023-03-08 Neophore Ltd Inhibitor compounds
WO2024173514A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Amide and ester-substituted imidazopyridine compounds
WO2024173524A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted benzimidazole compounds
WO2024173530A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted pyrazolo/imidazo pyridine compounds
WO2024173453A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted imidazopyridine compounds
WO2024189493A1 (en) 2023-03-10 2024-09-19 Breakpoint Therapeutics Gmbh Inhibitors of dna polymerase theta
WO2024209035A1 (en) 2023-04-05 2024-10-10 Forx Therapeutics Ag Parg inhibitory compounds
GB202306601D0 (en) 2023-05-04 2023-06-21 Cancer Research Tech Ltd Inhibitor compounds
GB202307924D0 (en) 2023-05-26 2023-07-12 Neophore Ltd Inhibitor compounds
GB2631507A (en) 2023-07-04 2025-01-08 Univ Liverpool Compositions
GB2631509A (en) 2023-07-04 2025-01-08 Univ Liverpool Compositions
WO2025046148A1 (en) 2023-09-01 2025-03-06 Forx Therapeutics Ag Novel parg inhibitors
WO2025056923A1 (en) 2023-09-15 2025-03-20 Cambridge Enterprise Limited Combination therapy
WO2025073792A1 (en) 2023-10-02 2025-04-10 Forx Therapeutics Ag Wrn inhibitory compounds
GB202315149D0 (en) 2023-10-03 2023-11-15 Celleron Therapeutics Ltd Combination therapy
WO2025073870A1 (en) 2023-10-03 2025-04-10 Forx Therapeutics Ag Parg inhibitory compound
GB202316595D0 (en) 2023-10-30 2023-12-13 Storm Therapeutics Ltd Inhibitory compounds
GB202316683D0 (en) 2023-10-31 2023-12-13 Storm Therapeutics Ltd Inhibitory compounds
WO2025093755A1 (en) 2023-11-01 2025-05-08 Forx Therapeutics Ag Novel parc inhibitors
GB202317368D0 (en) 2023-11-13 2023-12-27 Breakpoint Therapeutics Gmbh Novel compounds, compositions and therapeutic uses thereof
WO2025104443A1 (en) 2023-11-14 2025-05-22 Storm Therapeutics Ltd Inhibitory compounds
WO2025114480A1 (en) 2023-11-28 2025-06-05 Forx Therapeutics Ag Wrn inhibitory compounds
WO2025136811A1 (en) 2023-12-18 2025-06-26 Ideaya Biosciences, Inc. Chemical compounds and uses thereof
GB202319863D0 (en) 2023-12-21 2024-02-07 Breakpoint Therapeutics Gmbh Movel compounds, compositions and therapeutics uses thereof
GB202319864D0 (en) 2023-12-21 2024-02-07 Breakpoint Therapeutics Gmbh Novel compounds, compositions and therapeutic uses thereof
WO2025133396A1 (en) 2023-12-22 2025-06-26 Forx Therapeutics Ag Novel bicyclo heteroaryl parg inhibitors
WO2025133395A1 (en) 2023-12-22 2025-06-26 Forx Therapeutics Ag Bicyclic (hetero)arylene wrn inhibitory compounds
WO2025191176A1 (en) 2024-03-14 2025-09-18 Forx Therapeutics Ag Wrn inhibitory compounds
NL2037411B1 (en) 2024-04-08 2025-10-31 Univ Leiden Protac compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714249D0 (en) * 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents

Also Published As

Publication number Publication date
NZ522661A (en) 2004-07-30
NO20030055D0 (no) 2003-01-06
AU2001266232B2 (en) 2005-09-15
HUP0301742A3 (en) 2005-08-29
IS6668A (is) 2003-01-03
SK52003A3 (en) 2003-07-01
RU2003103603A (ru) 2004-08-20
CZ200331A3 (cs) 2003-04-16
JP2004504391A (ja) 2004-02-12
PL359181A1 (en) 2004-08-23
HUP0301742A2 (hu) 2003-09-29
CN1255392C (zh) 2006-05-10
WO2002008213A1 (en) 2002-01-31
IL153325A0 (en) 2003-07-06
BR0112225A (pt) 2003-05-06
CA2410562A1 (en) 2002-01-31
AU6623201A (en) 2002-02-05
EP1301498A1 (en) 2003-04-16
MXPA02012903A (es) 2004-07-30
KR20030022264A (ko) 2003-03-15
CN1440396A (zh) 2003-09-03
NO20030055L (no) 2003-01-06

Similar Documents

Publication Publication Date Title
EE200300015A (et) Kolhinooli derivaadid kui angiogeneesi inhibiitorid
EE200100509A (et) Aminopürimidiinid kui sorbitooldehüdrogenaasi inhibiitorid
IL153484A0 (en) Colchinol derivatives as angiogenesis inhibitors
AR028567A1 (es) Nuevos derivados de fenil-propargileter
EE200200140A (et) Pteridinoonid kui kinaasi inhibiitorid
ATE437862T1 (de) Pyrimidin-5-onderivate als ldl-pla2 inhibitoren
EE200900039A (et) KinasoliiniÁderivaadidÁangiogeneesiÁinhibiitoritenaÁjaÁvahehendid
AR028596A1 (es) Nuevos derivados de fenilglicina
EE200200237A (et) Kinasoliini derivaadid kui VEGF-i inhibiitorid
NO20030134D0 (no) Fremstilling av olefinderivater
PT1296981E (pt) Derivados substituidos da pirrolopiridinona uteis como inibidores da fosfodiesterase
DE60127098D1 (de) Inhibitoren der mucin-synthese
NO20026262L (no) Cyklopentyl-substituerte glutaramidderivater som inhibitorer av nöytral endopeptidase
DK1178986T3 (da) Furanonderivater som inhibitorer af cathepsin S
EE200300266A (et) Asendatud 8-arüülkinoliinid kui fosfodiesteraas-4inhibiitorid
EE200100611A (et) NOS inhibiitorite uued farmatseutilised kombinatsioonid
IL150806A0 (en) Piperidine-and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
ATE282038T1 (de) Kristallin form ii von cabergolin
PT1322592E (pt) Derivados substituidos de 1-aminobutan-3-ol
HUP0401641A3 (en) Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors
DE60031450D1 (de) Polymorph v von torasemid
EE200200389A (et) Imidasooli uued derivaadid
EE200100537A (et) Maduuraftalasiini derivaatide kasutamine proinflammatoorsete tsütokiinide inhibiitoritena
EP1222308A4 (en) INHIBITORS OF HISTONE ACETYL ANTIPROTOZOA TRANSFERASE
EP1674100A4 (en) ANGIOGENESIS INHIBITORS